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C L I N I C A L R E S E A R C H A R T I C L E
11-Oxygenated C19 Steroids Are the Predominant
Androgens in Polycystic Ovary Syndrome
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Angela E. Taylor,1,2 Jonathan L. Quanson,3 Karl-Heinz Storbeck,3,†
and Wiebke Arlt1,2,4,†
1Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham B15 2TT,
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Context: Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), but the exact
origin of hyperandrogenemia remains a matter of debate. Recent studies have highlighted the
importance of the 11-oxygenated C19 steroid pathway to androgen metabolism in humans. In this
study, we analyzed the contribution of 11-oxygenated androgens to androgen excess in women
with PCOS.
Methods: One hundred fourteen women with PCOS and 49 healthy control subjects underwent
measurement of serum androgens by liquid chromatography-tandem mass spectrometry. Twenty-
four–hour urinary androgen excretion was analyzed by gas chromatography-mass spectrometry.
Fasting plasma insulin and glucose were measured for homeostatic model assessment of insulin
resistance. Baseline demographic data, including body mass index, were recorded.
Results: As expected, serum concentrations of the classic androgens testosterone (P , 0.001),
androstenedione (P, 0.001), anddehydroepiandrosterone (P, 0.01)were significantly increased in
PCOS. Mirroring this, serum 11-oxygenated androgens 11b-hydroxyandrostenedione, 11-ketoan-
drostenedione, 11b-hydroxytestosterone, and 11-ketotestosterone were significantly higher in
PCOS than in control subjects, as was the urinary 11-oxygenated androgen metabolite 11b-
hydroxyandrosterone. The proportionate contribution of 11-oxygenated to total serum androgens
was significantly higher in patients with PCOS compared with control subjects [53.0% (interquartile
range, 48.7 to 60.3) vs 44.0% (interquartile range, 32.9 to 54.9); P , 0.0001]. Obese (n = 51) and
nonobese (n = 63) patients with PCOS had significantly increased 11-oxygenated androgens. Serum
11b-hydroxyandrostenedione and 11-ketoandrostenedione correlated significantlywithmarkers of
insulin resistance.
Conclusions: We show that 11-oxygenated androgens represent the majority of circulating an-
drogens in women with PCOS, with close correlation to markers of metabolic risk. (J Clin Endocrinol
Metab 102: 840–848, 2017)
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Androgen excess is a defining feature of polycysticovary syndrome (PCOS), which is one of the most
common endocrine disorders in women and is associated
with reproductive and metabolic complications (1). The
origin of androgen excess in PCOS has not been con-
clusively determined and may differ with phenotype
variability, but it is clear that both ovaries and adrenals
contribute to increased circulating androgens in affected
women. Previous work has highlighted that women with
PCOS show evidence of systemic upregulation of 5a-
reductase activity (2, 3), which activates testosterone (T)
to the most potent androgen, 5a-dihydrotestosterone.
Recently, it was reported that daughters of women with
PCOS show evidence of increased 5a-reductase activity
during infancy (4) prior to adrenarche- and puberty-
related increases in androgen production.
Traditionally, serum T has been used as a biochemical
marker for androgen excess in the context of PCOS, but
this has been fraught with difficulties, largely due to the
low circulating concentrations in women as well as the
specificity and sensitivity issues of the assays used. Re-
cently, the T precursor androstenedione (A4) has been
shown to be a more sensitive marker of PCOS-related
androgen excess and, in combination with T, predictive
of metabolic risk (5). These findings were confirmed by
another group (6), and the diagnostic value of A4 has
been recognized in recent position statements (7).
It has been known for decades that the adrenal is
capable of converting A4 to 11b-hydroxyandrostenedione
(11OHA4) (8), catalyzed by the 11b-hydroxylase activity
of the cytochrome P450 enzyme cytochrome P450 11b-
hydroxylase, but it was thought to represent an insig-
nificant metabolite. However, recent studies have dem-
onstrated that 11OHA4 is a major product of adrenal
steroidogenesis (9) and that its downstream conversion
through the 11-oxygenated C19 steroid pathway (Fig. 1)
generates 2 steroids, 11-ketotestosterone (11KT) and 11-
keto-5a-dihydrotestosterone (10), that bind and acti-
vate the androgen receptor with affinities and potencies
similar to that of T and 5a-dihydrotestosterone, re-
spectively (11).
The role of 11-oxygenated C19 steroids in PCOS has
not been comprehensively delineated. A number of pre-
vious studies have attempted to evaluate the role of
11OHA4 in PCOS, but results have been inconclusive
(12–14). To our knowledge, none of these studies ex-
amined the role of other 11-oxygenated androgens in
global androgen metabolism in women with PCOS.
Furthermore, the majority of these early studies relied on
radioimmunoassays, now largely surpassed by the advent
of modern liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) assays. Therefore, we have ex-
amined the contribution of this poorly characterized
androgen pathway to overall androgen excess in a large
Figure 1. Schematic of androgen synthesis illustrating the classic androgen pathway (gray boxes) and the steroids of the 11-oxygenated
androgen pathway (black boxes). Dotted lines relate distinct steroids to their corresponding urinary steroid metabolite. Abbreviations: 11KDHT,
11-ketodihydrotestosterone; 17OH-PREG, 17a-hydroxypregnenolone; CYB5A, cytochrome b5; CYP11B1, cytochrome P450 11b-hydroxylase;
CYP17A1, cytochrome P450 17a-hydroxylase/17,-20-lyase; DHT, 5a-dihydrotestosterone; HSD11B2, 11b-hydroxysteroid dehydrogenase type 2;
HSD3B, 3b-hydroxysteroid dehydrogenase; PREG, pregnenolone; SRD5A, steroid 5a-reductase; SULT2A1, sulfotransferase family 2A member 1.
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cohort of women with PCOS by mass spectrometry–
based analysis of serum and urinary steroids, in com-
parison with a healthy female control cohort and in re-
lation to surrogate makers of metabolic risk.
Materials and Methods
Subjects and clinical protocol
Women with PCOS aged between 18 and 40 years were
recruited from outpatient clinics at University Hospital Bir-
mingham and Birmingham Women’s Hospital. Full ethical
approval was obtained from the South Birmingham and
Edgbaston Research Ethics Committees (reference numbers
LREC5835 and 12/WM/0206). All participants provided
written informed consent. PCOS was diagnosed according to
the Rotterdam European Society of Human Reproduction and
Embryology 2004 criteria, requiring the presence of 2 or more
of the following features: oligo/anovulation, clinical signs of
hyperandrogenism or biochemical androgen excess, and poly-
cystic ovaries on ultrasound (1). Other potential causes of
oligomenorrhea and androgen excess were excluded by history,
physical examination, and biochemical assessment. Healthy
control subjects were recruited via local advertisement, with the
exclusion of PCOS on clinical and biochemical grounds. This
was done by obtaining a menstrual history, by direct ques-
tioning regarding clinical features of androgen excess, and by
biochemical analysis of serum androgens. Individuals with
menstrual disturbance and clinical or biochemical hyper-
androgenism were excluded. Exclusion criteria for the study
were as follows: recent glucocorticoid treatment (within
3 months), pregnancy, age younger than 18 or older than
40 years, recent oral contraceptive use (within 3 months), hyper-
prolactinemia, thyroid disorders, and frank hyperglycemia.
Study participants attended the National Institutes of Health
Research/Wellcome Trust Clinical Research Facility at Uni-
versity Hospital Birmingham after an overnight fast. A pre-
collected 24-hour urine sample for urinary steroid metabolite
analysis was provided by each patient on the morning of as-
sessment. Baseline anthropometric data were collected, and
blood samples were drawn for fasting glucose and insulin and
for measurement of the serum concentrations of classic and 11-
oxygenated C19 steroids.
Serum steroid analysis
All serum steroids were measured by LC-MS/MS. Dehy-
droepiandrosterone sulfate (DHEAS) was extracted from 20 mL
serum by the addition of 20 mL 0.1 mM ZnSO4 and 100 mL
acetonitrile and quantified in negative mode using a mass spec-
trometer (Xevo TQ; Waters, Milford, MA) coupled to an
ACQUITYUPLC system (Waters) as previously described (5, 15).
All other steroids were extracted from 400 mL serum using 2 mL
methyl tert-butyl ether as previously described (5, 16, 17). Serum
T, A4, dehydroepiandrosterone (DHEA), 11OHA4, 11b-
hydroxytestosterone (11OHT), and 11KT were quantified us-
ing a mass spectrometer (Xevo TQ-S; Waters) coupled to an
ACQUITY UPLC system (Waters). The serum steroids were sep-
arated using a UPLC high-strength silica T3 column (2.1 mm 3
50 mm, 1.8 mm) (Waters) and 1% formic acid (A) and 100%
methanol (B) as mobile phases. Separation was achieved using a
5-minute linear gradient from 55%A to 75%B at a constant flow
rate of 0.6mL/min and a column temperature of 50°C. All steroids
were analyzed in multiple reaction monitoring using the settings
reported by Quanson et al. (16). Comprehensive validation data
for the 11-oxygenated steroids are shown in Supplemental Table 1.
Serum 11-ketoandrostenedione (11KA4) was quantified using an
ACQUITY UPC2 system (Waters) coupled to a mass spectrometer
(Xevo TQ-S; Waters) as previously reported (16). Data collection
and analysis were performed using MassLynx 4.1 (Waters). Ste-
roids were identified by matching retention times and 2 mass
transitions and were quantified by referring to a linear calibration
serieswith appropriate deuterated reference compounds as internal
standards.
Urinary steroid measurement
Urinary steroid metabolites were measured using quantita-
tive gas chromatography-mass spectrometry in selected ion
monitoring mode as previously described (18). The steroid
metabolites relevant to this study are shown in Table 1 and
Figure 1. The production of steroids from the classic androgen
pathway was measured by the quantification of the major andro-
gen metabolites androsterone (An) and etiocholanolone (Et). The
major 11-oxygenated C19 metabolite 11b-hydroxyandrosterone
(11b-OH-An) was measured to assess the contribution of the
11-oxygenated C19 steroid pathway.
Biochemical analysis
Insulin was measured using a commercially available assay
(Mercodia, Uppsala, Sweden) according to the manufacturer’s
instructions. Plasma glucose was measured using the 2300
STAT PLUS analyzer (YSI Life Sciences, Yellow Springs, OH).
Homeostasis model assessment of insulin resistance (HOMA-
IR) was calculated using the formula [fasting glucose (mmol/L)
*fasting insulin (mU/L)/22.5].
Statistical analysis
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS), Version 22. Results are presented as
median [interquartile range (IQR)] unless otherwise stated. For
comparison of single variables, t tests (paired or unpaired as
appropriate) were used. Nonparametric equivalents where used
where data were not normally distributed. One-way analysis of
variance with post hoc Tukey testing was used for multiple
comparisons between different groups. Due to nonnormality of
data distribution, Spearman’s Rho was used for correlation
testing between continuous variables. Differences were con-
sidered statistically significant at P , 0.05.
RESULTS
Baseline demographics of patients and control
subjects
A total of 49 control subjects and 114 women with
PCOSwere included in the study. After application of the
Rotterdam criteria, the prevalence of the 4 Rotterdam-
derived phenotypes was as follows: phenotype A (an-
drogen excess, anovulation, and polycystic ovaries),
59.7%; phenotype B (androgen excess, polycystic ova-
ries), 6.9%; phenotype C (androgen excess, anovulation),
23.6%; phenotype D (anovulation, polycystic ovaries)
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9.7%. Control subjects and women with PCOS were
matched for age (P = 0.18); however, women with PCOS
had a significantly higher body mass index (BMI) than
age-matched control subjects [median BMI 31.2 kg/m2
(IQR, 27.0 to 36.2) vs 23.7 kg/m2 (IQR, 21.2 to 26.1),
respectively; P, 0.001] (Table 1). Using a BMI cut-off of
30 kg/m2, 51 and 63womenwith PCOSwere categorized
as nonobese and obese, respectively. The BMI in non-
obese women with PCOS did not differ from control
subjects (P = 0.35). HOMA-IR values were significantly
higher in obese patients with PCOS than in control
subjects (P , 0.001).
Both classic and 11-oxygenated androgens are
significantly increased in PCOS
LC-MS/MS analysis of serum androgens in the pa-
tients with PCOS revealed significantly increased con-
centrations of the classic androgen T and its precursors A4
and DHEA (all P, 0.001) as well as DHEAS (P = 0.002)
when compared with control subjects (Fig. 2).
Serum concentrations of the 11-oxygenated andro-
gens 11OHA4, 11OHT, 11KA4, and 11KT were all
significantly higher in the PCOS cohort (P , 0.001
for 11OHA4 and 11KA4; P , 0.01 for 11OHT and
11KT) (Fig. 2). Indeed, the proportionate contribution of
11-oxygenated steroids to total serum androgens was
significantly higher in patients with PCOS than in control
subjects [53.0% (IQR, 48.7 to 60.3) vs 44.0% (IQR, 32.9
to 54.9); P , 0.0001] (Fig. 3). Serum concentrations of
11KT were significantly higher than those of T in control
subjects and women with PCOS (P , 0.001 for both). It
should be noted that the lower limit of quantification for
11OHTwas 0.65 nmol/L; although 11OHTwas detected
in the majority of samples, only a single control patient
had a value above the lower limit of quantification. By
contrast, 22 patients with PCOS had values above this
cut-off.
Correspondingly, urinary 24-hour excretion of the
classic androgen metabolites An and Et was significantly
higher in women with PCOS (P = 0.004 and 0.005, re-
spectively) (Fig. 2).
Similarly, the excretion of the urinary metabolite of
11OHA4, 11b-OH-An, was significantly increased in
patients with PCOS [595 (IQR, 347 to 861) vs 353 (IQR,
171 to 487) in control subjects; P , 0.001) (Fig. 2).
11-oxygenated androgens are increased in PCOS
independent of BMI
Serum concentrations of classic androgens (T, A4,
DHEA, and DHEAS) and 11-oxygenated androgens
Table 1. Baseline Characteristics and Biochemical Data in the Healthy Control Subjects and the PCOS Cohort,
with Additional Comparison of Nonobese and Obese Patients with PCOS
Controls (n = 49) All PCOS (n = 114) Nonobese PCOS (n = 51) Obese PCOS (n = 63)
Age, y 28 (23–32) 30 (24–36) 29 (24–36) 30 (24–37)
BMI, kg/m2 23.7 (21.2–26.1) 31.2 (27.0–36.2)a 26.0 (23.3–28.0) 35.5 (32.8–38.9)a,b
HOMA-IR 0.6 (0.4–0.9) 1.7 (0.9–3.6)a 0.9 (0.5–1.6) 2.7 (1.5–4.9)a,b
SHBG, nmol/L 58.7 (40.9–81.8) 30.9 (20.8–42.1) a 36.8 (22.4–57.3)a 26.7 (18.2–33.9)a
Serum androgens (nmol/L)
T 0.3 (0.2–0.5) 0.7 (0.5–1.0)a 0.7 (0.5–1.0)c 0.7 (0.5–1.1)c
A4 5.9 (3.3–9.2) 26.8 (16.9–35.2)a 24.4 (15.5–35.0)a 29.2 (17.7–36.0)a
DHEA 7.1 (4.2–11.8) 14.1 (10.4–18.2)c 14.7 (10.6–18.8)d 13.5 (10.4–17.9)
DHEAS (mmol/L) 6.0 (3.4–9.6) 8.1 (5.5–12.2)c 10.1 (5.6–13.5)c 7.6 (5.4–11.7)
FAI 0.6 (0.3–0.9) 2.2 (1.4–4.0)a 1.8 (1.2–3.5)d 3.0 (1.6–4.3)a
11OHA4 6.8 (4.9–12.5) 31.7 (16.8–47.8)a 30.5 (16.1–55.3)a 34.4 (17.0–46.8)a
11KA4 2.7 (2.0–3.9) 13.4 (8.5–18.8)a 13.0 (8.3–17.6)a 14.2 (8.8–19.8)a
11OHT 0.2 (0.1–0.3) 0.4 (0.3–0.5)c 0.4 (0.3–0.5)c 0.4 (0.3–0.6)c
11KT 1.5 (1.2–1.8) 2.4 (1.8–3.9)c 2.4 (1.4–3.4) 2.6 (1.9–4.3)c
Urinary androgen metabolites (mg/24 h)
U-An 1231 (856–1814) 2426 (1475–3634)c 2432 (1451–3719) 2376 (1459–3634)d
U-Et 1394 (767–1833) 2071 (1305–3005)c 1991 (1147–2840) 2125 (1425–3077)c
U-DHEA 388 (145–1209) 536 (185–2009) 590 (129–2171) 461 (198–1832)
U-11b-OH-An 353 (171–487) 595 (347–861)a 595 (438–841)c 598 (343–899)a
Abbreviations: FAI, free androgen index; SHBG, sex hormone-binding globulin; U-11b-OH-An, urinary 11b-hydroxyandrosterone; U-An, urinary an-
drosterone; U-DHEA, urinary dehydroepiandrosterone; U-Et, urinary etiocholanolone.
Data are presented as median and IQR. Statistical comparison was carried out by analysis of variance with post hoc Tukey testing. Significance levels are
indicated by the footnotes.
aP , 0.001 as compared with healthy control subjects.
bP , 0.001 for the comparison nonobese vs obese patients with PCOS.
cP , 0.01.
dP , 0.05.
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(11OHA4, 11KA4, 11OHT, and 11KT) did not differ
significantly between obese and nonobese women with
PCOS. Similarly, urinary excretion of classic androgen
metabolites An, Et, and DHEA and the 11-oxygenated
metabolite 11b-OH-An were similar in nonobese and
obese women with PCOS.
We examined this further by comparing the nonobese
PCOS group (n = 51) with healthy control subjects (n = 49).
Nonobese women with PCOS were matched for age,
BMI, and HOMA-IR with healthy control subjects
(Table 1). Serum concentrations of the classic androgens T
(P , 0.01), A4 (P , 0.001), DHEA (P , 0.05), and
DHEAS (P , 0.01) were all higher in
the nonobese PCOS cohort than in
BMI-matched control subjects. Mir-
roring this, serum levels of 11OHA4
and 11KA4 (P, 0.001 for both) aswell
as 11OHT (P , 0.01) were all signifi-
cantly increased in nonobese women
with PCOS compared with control
subjects. There was a trend toward
higher serum levels of 11KT in the
nonobese PCOS group, but this did not
reach statistical significance (P = 0.10).
Looking at urinary androgen meta-
bolism, excretion of the 11-oxygenated
androgen metabolite 11b-OH-An was
significantly higher in the nonobese
PCOS cohort [595 (IQR, 438 to 841) vs
Figure 2. Serum concentrations of (A, B) classic and (C–F) 11-oxygenated steroids in women with PCOS (n = 114) and healthy sex- and age-
matched control subjects (n = 49). (G–I) Major urinary androgen metabolite deriving from the classic androgen pathway, An and etiocholanolone
(Et), and the 11b-hydroxyandrostenedione metabolite 11b-OH-An.
Figure 3. Relative contribution (median; %) of the classic androgen pathway (DHEA, A4, T;
shades of blue) and the 11-oxygenated C19 steroid pathway (11OHA4, 11KA4, 11OHT,
11KT; shades of red) to the total circulating androgenic steroid pool, comparing patients with
PCOS (n = 114) with sex- and age-matched healthy control subjects (n = 49).
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353 (IQR, 171 to 487) in controls; P = 0.002], whereas
there was only a trend toward significantly higher urinary
excretion of An (P = 0.07). Excretion of Et and DHEA did
not differ between nonobese women with PCOS and
control subjects. Serum 11OHA4, 11KA4, 11OHT, and
11KT all correlated significantly with urinary excretion of
11b-OH-An (R = 0.39, 0.39, 0.33, and 0.40, respectively;
P , 0.01 for each; for details see Supplemental Table 2).
11-oxygenated androgens correlatewithmarkers of
metabolic risk
The 11-oxygenated androgen precursors 11OHA4
and 11KA4 correlated significantly with BMI (R = 0.31,
P, 0.01 and R = 0.37, P, 0.01, respectively). Both also
had significant correlations with insulin (R = 0.19,
P,0.05 andR=0.30,P,0.01, respectively) andHOMA-
IR (R=0.21,P,0.05andR=0.32,P,0.01, respectively).
By contrast, we did not observe significant associations
with BMI, insulin, or HOMA-IR for 11KT and 11OHT.
The free androgen index (FAI) (serumTx100/SHBG)
correlated significantly with BMI, insulin, and HOMA-
IR (P, 0.01 for each) (Table 2). The FAI also correlated
positively with all serum 11-oxygenated androgens.
Similar to the findings with 11OHA4 and 11KA4, serum
A4 correlated with BMI, insulin, and HOMA-IR (R =
0.44, 0.27, and 0.29, respectively; all P, 0.01). Serum T
correlated weakly with BMI only (R = 0.17, P , 0.05),
whereas serumDHEA andDHEAS did not correlate with
BMI, insulin, or HOMA-IR.
Discussion
We have performed a comprehensive comparison of
classic and 11-oxygenated androgens in women with
PCOS. We found that all measured 11-oxygenated
steroids, including the potent androgen 11KT, were sig-
nificantly increased in women with PCOS compared with
control subjects. Previous studies from the early 1990s had
reported increased levels of 11OHA4 in PCOS. However,
those studies were mostly reliant on immunoassays rather
than sensitive and specific mass spectrometry and con-
tained no data on further downstream metabolism of
11OHA4 (12–14). Intriguingly, we could show that 11-
oxygenated androgens constitute the majority of the cir-
culating, unconjugated androgen excess in PCOS, which
strongly suggests that they are important contributors to
PCOS-related hyperandrogenism. Although it could be
argued that the shift in favor of 11-oxygenated androgens
is due to the abundance of the inactive androgen pre-
cursors 11OHA4 (34.9%) and 11KA4 (16.4%), the
levels of active 11-oxygenated androgens also exceeded
those of classical androgens. Indeed, median circulat-
ing concentrations of 11KT were more than threefold
higher than those of T in PCOS, traditionally the an-
drogen measured most commonly in clinical practice
in the disorder. It is therefore highly likely that 11KT is
a major player in PCOS-related androgen excess, es-
pecially given that 11KT can activate the androgen
receptor in a similar manner to T (9–11, 19–21), and
can be converted to the even more potent androgen
11-ketodihydrotestosterone in peripheral target tissue
(10, 11). Further studies are required to delineate the
relative contributions of these androgens and their
downstream activation in target tissues on metabolic
risk in PCOS. These data also underpin the crucial role
of the adrenal gland in contributing to PCOS-related an-
drogen excess because the first step of the 11-oxygenated
androgen pathway is dependent on the 11b-hydroxylation
of A4 to 11OHA4 by adrenal cytochrome P450 11b-
hydroxylase.
Table 2. Correlation Analysis (Spearman’s Rho, All Patients) for Serum Androgens with Baseline
Demographics and Metabolic Data in the PCOS and Control Cohorts (n = 163)
Age BMI Glucose Insulin
HOMA-
IR T A4 DHEA DHEAS 11OHA4 11KA4 11OHT 11KT FAI
Age 0.15 0.188a 2 0.08 2 0.042 2 0.119 0.082 2 0.166 2 0.255b 2 0.038 2 0.017 2 0.004 2 0.005 2 0.108
BMI 0.15 0.330b 0.587b 0.602b 0.170a 0.439b 0.112 0.02 0.308b 0.371b 0.121 0.171 0.464b
Glucose 0.188a 0.330b 0.332b 0.440b 2 0.074 2 0.004 2 0.05 2 0.021 0.054 0.011 0.069 0.037 0.075
Insulin 2 0.08 0.587b 0.332b 0.994b 0.137 0.274b 0.129 0.054 0.198a 0.302b 2 0.033 0.077 0.396b
HOMA-
IR
2 0.042 0.602b 0.440b 0.994b 0.112 0.287b 0.118 0.043 0.215a 0.316b 2 0.024 0.065 0.380b
T 2 0.119 0.170a 2 0.074 0.137 0.112 0.352b 0.335b 0.390b 0.379b 0.420b 0.359b 0.185a 0.814c
A4 0.082 0.439b 2 0.004 0.274b 0.287b 0.352b 0.589b 0.237b 0.818b 0.864b 0.267b 0.519b 0.515b
DHEA 2 0.166a 0.112 2 0.05 0.129 0.118 0.335b 0.589b 0.489b 0.620b 0.580b 0.512b 0.537b 0.438b
DHEAS 2 0.255b 0.02 2 0.021 0.054 0.043 0.390b 0.237b 0.489b 0.351b 0.349b 0.437b 0.289b 0.433b
11OHA4 2 0.038 0.308b 0.054 0.198a 0.215a 0.379b 0.818b 0.620b 0.351b 0.883b 0.461b 0.514b 0.475b
11KA4 2 0.017 0.371b 0.011 0.302b 0.316b 0.420b 0.864b 0.580b 0.349b 0.883b 0.373b 0.595b 0.526b
11OHT 2 0.004 0.121 0.069 2 0.033 2 0.024 0.359b 0.267b 0.512b 0.437b 0.461b 0.373b 0.516b 0.346b
11KT 2 0.005 0.171 0.037 0.077 0.065 0.185a 0.519b 0.537b 0.289b 0.514b 0.595b 0.516b 0.23a
FAI 2 0.108 0.464b 0.075 0.396b 0.380b 0.814c 0.515b 0.438b 0.433b 0.475b 0.526b 0.346b 0.23a
aSignificant at P , 0.05.
bSignificant at P , 0.01.
cSignificant at P , 0.001.
doi: 10.1210/jc.2016-3285 press.endocrine.org/journal/jcem 845
These results are in broad agreement with a recent
study that investigated the contribution of 11-oxygenated
androgens to the androgen pool in another androgen
excess state, classic congenital adrenal hyperplasia due to
21-hydroxylase deficiency (21OHD). In their study,
Turcu et al. (22) found that 11OHA4, 11OHT, 11KA4,
and 11KT were all significantly elevated in male and
female patients with 21OHD when compared with age-
and sex-matched control subjects. The authors concluded
that the 11-oxygenated androgens represent potentially
novel biomarkers of adrenal-derived androgen excess
and that 11KT may be the most clinically relevant an-
drogen in patients with 21OHD. However, there are
differences in the absolute serum concentrations of the
11-oxygenated steroids reported for the control samples
measured in our study and that of Turcu et al. (22). Rege
et al. (9) have also previously measured the levels of
11-oxygenated C19 steroids in the adrenal vein and
peripheral circulation of female patients with primary
aldosteronism. For comparison, we have pulled together
the data from the 2 previous studies in direct comparison
with our results in Table 3. In all cases, 11OHA4 is the
most abundant 11-oxygenated C19 steroid, and 11KT
levels are higher than those of 11OHT. Differences in
absolute levels may be ascribed to differences in the
composition of the control groups, sample sizes, and sex-
specific variability as well as differences in extraction and
LC-MS/MS protocols (23). For example, the control
group for the 21OHD study consisted of bothmale (n = 19)
and female (n = 19) subjects, with an age range between
3 and 59 years, whereas the control group from this
study consisted only of female subjects (n = 49) aged 18
to 40 years. To the best of our knowledge, deuterated
internal standards for 11KA4, 11OHT, and 11KT are not
currently commercially available, thereby complicating
the quantification of these steroids by LC-MS/MS.
Nonetheless, comparisons between control groups and
patient groups within these individual studies un-
equivocally demonstrate that the 11-oxygenated andro-
gens are significantly elevated in both PCOS and
21OHD. Further studies with larger cohorts, as well as
with the use of deuterated 11-oxygenated internal stan-
dards, are therefore required to establish reliable refer-
ence ranges in health and disease.
This study has validated our observation from pre-
viously published work that A4 is a surrogate marker of
metabolic risk in PCOS, confirming significant positive
associations with BMI, fasting insulin, and HOMA-IR
(5). In this study we found that the serum concentrations
of the 11-oxygenated androgen precursors 11OHA4 and
11KA4 also significantly correlate with BMI, fasting
insulin, and HOMA-IR. Hence, these steroids may have
additional value as surrogate markers of metabolic risk in
PCOS. This finding is perhaps not entirely surprising
given that 11OHA4 and 11KA4 are derivatives of A4 and
that highly significant correlations are observed between
all 3 steroids (Table 2).
Not only obese but also nonobese women with PCOS
had significantly higher levels of 11OHA4, 11KA4, and
11OHT than BMI-matched healthy control subjects, and
levels of all 11-oxygenated androgens did not differ be-
tween obese and nonobese women with PCOS. By con-
trast, HOMA-IR was only significantly increased in
the obese patients. It is unclear why the serum levels
of 11OHA4 and 11KA4 did not differ between obese
and nonobese women with PCOS given the above-
described significant association of these steroids with
BMI. Unfortunately, our patient number did not allow a
Table 3. Serum Concentrations of Classical and 11-Oxygenated Androgens
Steroid
(nmol/L)
Adrenal Vein
Study—Rege et al. (9),
Mean 6 SEM
CAH Study—Turcu et al. (22),
Median (IQR)
PCOS—This Study,
Median (IQR)
Adrenal
Vein
(n = 7; all
women)
Periphery
(n = 7; all
women)
Controls
(n = 38; 19 women)
21OHD
(n = 38; 19 women)
Controls
(n = 49; all
women)
PCOS
(n = 114; all
women)
DHEAS 38276 1317 2210 6 321 3793.4 (1585.1–5066.5) 508.7 (213.0–1745.2) 6038 (3402–9522) 8133 (5515–12,240)
DHEA 125 6 56.9 5.85 6 1.01 6.0 (4.1–11.0) 1.0 (0.55–2.9) 7.1 (4.2–11.8) 14.1 (10.4–18.2)
A4 79.0 6 46.9 1.90 6 0.47 1.5 (0.77–2.2) 5.4 (2.5–13.6) 5.9 (3.6–9.2) 26.8 (16.9–35.2)
T 0.78 6 0.26 0.44 6 0.05 0.90 (0.42–10.7) 2.8 (1.3–5.6) 0.3 (0.2–0.5) 0.7 (0.5–1.0)
11OHA4 157 6 96.2 1.90 6 0.42 3.9 (2.3–5.1) 11.6 (6.2–26.2) 6.8 (4.9–12.3) 31.7 (16.8–47.8)
11KA4 0.99 6 0.33 0.46 6 0.07 1.0 (0.67–1.4) 3.2 (1.9–4.8) 2.7 (2.0–3.8) 13.4 (8.5–18.8)
11OHT 0.48 6 0.17 0.22 6 0.04 0.49 (0.30–0.69) 1.9 (0.69–3.4) 0.2 (0.1–0.3) 0.4 (0.3–0.5)
11KT 0.39 6 0.09 0.44 6 0.03 1.7 (0.96–2.6) 5.7 (3.5–12.1) 1.5 (1.2–1.8) 2.4 (1.8–3.9)
Data are as measured in 3 separate studies: a comparison of adrenal vein and peripheral blood concentrations in women with primary aldosteronism (9);
healthy control subjects vs patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency receiving routine steroid therapy (22); and this
study comparing PCOS with healthy control subjects.
Abbreviations: CAH, congenital adrenal hyperplasia; SEM, standard error of the mean.
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correlation analysis split by subgroup with sufficient
statistical power. A4 is already a suitable surrogate
marker of metabolic risk in PCOS. It is, however, im-
portant that future studies investigate the role of these
androgen precursors in metabolic target tissues because
their metabolism and consequent activity may well differ.
Our results may also suggest that androgen excess
precedes androgen-driven insulin resistance and sub-
sequent weight gain in the pathophysiological sequence
of PCOS. Androgen-mediated effects on adipose tissue
function and fat mass expansion are increasingly rec-
ognized (24), and classic androgen pathway serum an-
drogens correlate closely with adipose tissue mass in
women (25). Prenatal androgen exposure is associated
with adipocyte hypertrophy and increased fat mass in
rodent and sheep models (26, 27). Women with early-
onset androgen excess in PCOS may therefore be pre-
disposed to androgen-mediated obesity in later adulthood,
fueling a vicious circle of androgen excess, weight gain,
and hyperinsulinemia (5).
A key factor in peripheral androgen metabolism is
aldo-keto reductase type 1C3 (AKR1C3), which converts
A4 to T. AKR1C3 is highly expressed in adipose tissue
(28), and its expression in subcutaneous adipose tissue is
increased not only in subjects with simple obesity (29) but
also in women with PCOS (30). In our study, BMI
correlated significantly with serum T, supporting the
conversion of A4 to T by AKR1C3 in adipose tissue.
Conversely, 11OHA4 is not a substrate for AKR1C3 (10)
and thus cannot be converted to 11OHT in adipose
tissue. Similarly, although 11KA4 is a substrate for
AKR1C3 (10), the expression of 11b-hydroxysteroid
dehydrogenase type 1 in adipose tissue (31)mayminimize
its conversion to 11KT because 11bHSD1 efficiently
converts 11KA4 to 11OHA4, which is not a substrate for
AKR1C3 (10, 32). These conversions are supported by
the observation that although 11OHT and 11KT levels
are significantly elevated in PCOS, neither 11OHT nor
11KT correlated with BMI. This finding further supports
the idea that androgen excess drives weight gain in PCOS.
Our observations therefore provide further evidence for a
causal link between androgen excess and metabolic
dysfunction in PCOS.
In summary, we have demonstrated that 11-oxygen-
ated androgens are significantly elevated in obese and
nonobese women with PCOS and cumulatively consti-
tute a greater proportion of total circulating androgens
than classic androgens. This observation has not been
replicated in healthy control subjects, where classic an-
drogens appear to constitute the majority of the cir-
culating androgen pool. Intriguingly, 11KT circulates in
significantly higher concentrations than T, both in women
with PCOS and control subjects, opening up avenues for
the exploring the origins of androgen excess in PCOS.
Close correlation of a number of 11-oxygenated steroids
with hyperinsulinemia further highlight a potential im-
portant role for these steroids as biomarkers not only
of androgen excess but also of insulin resistance, met-
abolic dysfunction, and tissue-specific androgen acti-
vation in PCOS.
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